NAFLD is expected to be the most prevalent liver disease in the post-HCV era. The clinical impact of NAFLD and the benefit of screening with biochemical based algorithms is a metter of concern.
Should we screen for NAFLD/NASH in HIV patients? / Guaraldi, G., Malagoli, A., Stentarelli, C., Manicardi, M., Zona, S., Carli, F., Menozzi, M., Santoro, A., Franceschini, E., Mussini, C.. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - STAMPA. - 20:(2015), pp. 65-66. (17th International Wokshop on Co-morbidities and Adverse Drug Reaction in HIV Barcellona 20-22 ottobre 2015).
Should we screen for NAFLD/NASH in HIV patients?
GUARALDI, Giovanni;MALAGOLI, Andrea;STENTARELLI, Chiara;Manicardi, Marcella;ZONA, Stefano;CARLI, FEDERICA;Menozzi, Marianna;SANTORO, ANTONELLA;FRANCESCHINI, Erica;MUSSINI, Cristina
2015
Abstract
NAFLD is expected to be the most prevalent liver disease in the post-HCV era. The clinical impact of NAFLD and the benefit of screening with biochemical based algorithms is a metter of concern.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
